Testing a new lung cancer drug combined with chemotherapy

Plain-English translation of NCT06692738 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This study is testing a new drug called to see if it works better than an existing immunotherapy drug () when combined with chemotherapy for people with advanced squamous cell lung cancer. Both groups will receive chemotherapy plus one of these two medications. The goal is to find out which combination helps patients live longer and control their cancer better.

Squamous lung cancer is an aggressive type that is often diagnosed at a late stage. While immunotherapy drugs have helped some patients, doctors are still looking for more effective treatments, especially for people whose tumors have specific characteristics. This medication is being tested to see if it offers a better option.

Do you qualify?

You likely qualify if…

you have been diagnosed with squamous cell lung cancer that has spread beyond the lungs or cannot be surgically removed
your tumor shows a specific marker called PD-L1 on at least 1% of tumor cells
you have not received chemotherapy or immunotherapy for lung cancer before
you have at least one measurable tumor that has not been previously treated with radiation
your organs and bone marrow are functioning well enough to tolerate chemotherapy

You likely don't qualify if…

you have received any prior chemotherapy or immunotherapy for lung cancer
you have untreated brain metastases (though stable, treated brain tumors may be acceptable)
you have an active autoimmune disease requiring ongoing immunosuppressive treatment
you have active tuberculosis or a severe active infection
you have a history of another cancer diagnosed within the last 2 years

What participation looks like

If you join this trial, you will be randomly assigned to receive either or combined with chemotherapy ( and or ). You will receive chemotherapy infusions, followed by ongoing treatment with your assigned medication. You will have regular clinic visits for blood tests, scans, and check-ups to monitor how well the treatment is working and any side effects you experience.

AI-generated summary from trial data · Jul 17, 2026 · Not medical advice

Trial locations(312 sites)

United States

Research Site, Tucson, Arizona

Research Site, Springdale, Arkansas

Research Site, Anaheim, California

Research Site, Beverly Hills, California

Research Site, Loma Linda, California